{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:35:01Z","timestamp":1782311701421,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008799","name":"Gilead Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.numecd.2021.06.020","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T13:38:29Z","timestamp":1625751509000},"page":"2887-2894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatic fibrosis of any origin in a large population of type 2 diabetes patients"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4709-8696","authenticated-orcid":false,"given":"Carlo B.","family":"Giorda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Picariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tartaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Linzalata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gnavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2021.06.020_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.numecd.2021.06.020_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","article-title":"The diagnostic accuracy of US, CT, MRI and 1H-MRS for the 2011. Evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis","volume":"21","author":"Bohte","year":"2011","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.numecd.2021.06.020_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1478-3231.2011.02482.x","article-title":"Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalence and correlated factors","volume":"31","author":"Leite","year":"2011","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.numecd.2021.06.020_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.numecd.2021.06.020_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.numecd.2006.08.004","article-title":"Diabetes and liver disease: an ominous association","volume":"17","author":"Moscatiello","year":"2007","journal-title":"Nutr Metabol Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.numecd.2021.06.020_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2012-3093","article-title":"Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.numecd.2021.06.020_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"issue":"25","key":"10.1016\/j.numecd.2021.06.020_bib8","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4254\/wjh.v7.i25.2610","article-title":"Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease","volume":"7","author":"Puchakayala","year":"2015","journal-title":"World J Hepatol"},{"issue":"7","key":"10.1016\/j.numecd.2021.06.020_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.06.020_bib10","first-page":"64 1388","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.numecd.2021.06.020_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.numecd.2021.06.020_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.06.020_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/oem.2007.034777","article-title":"Approaches for estimating prevalence ratios","volume":"65","author":"Deddens","year":"2008","journal-title":"Occup Environ Med"},{"issue":"4","key":"10.1016\/j.numecd.2021.06.020_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.numecd.2021.06.020_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. Adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.numecd.2021.06.020_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2021.06.020_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2017.10.023","article-title":"Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients","volume":"135","author":"Giorda","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.numecd.2021.06.020_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2010.11.007","article-title":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?","volume":"54","author":"Targher","year":"2011","journal-title":"J Hepatol"},{"issue":"Pt 1","key":"10.1016\/j.numecd.2021.06.020_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2015.02.018","article-title":"Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link?","volume":"418","author":"Asrih","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.numecd.2021.06.020_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hep.510280119","article-title":"Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity","volume":"28","author":"Petrides","year":"1998","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.numecd.2021.06.020_bib21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/cncr.24982","article-title":"Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma","volume":"116","author":"Hassam","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.numecd.2021.06.020_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.numecd.2021.06.020_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/15680266113136660067","article-title":"Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies","volume":"8","author":"Karlstad","year":"2013","journal-title":"Curr Drug Saf"},{"issue":"2","key":"10.1016\/j.numecd.2021.06.020_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/edrv-5-2-356","article-title":"Growth-stimulatory actions of insulin in\u00a0vitro and in\u00a0vivo","volume":"5","author":"Straus","year":"1984","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.numecd.2021.06.020_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11892-017-0955-3","article-title":"Insulin and its cardiovascular effects: what is the current evidence?","volume":"17","author":"Dongerkery","year":"2017","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.numecd.2021.06.020_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2931985","article-title":"The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes","author":"Forlani","year":"2016","journal-title":"J Diabetes Res"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321003161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321003161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:16:43Z","timestamp":1760545003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321003161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0939475321003161"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.06.020","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic fibrosis of any origin in a large population of type 2 diabetes patients","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}